Non-small cell lung cancer
Conditions
Interventions
Nab-paclitaxel 100mg/m2 on day 1,8,15 Carboplatin AUC6 q3weeks , 4 cycles.
Sponsors
Department of Thoracic Surgery , Faculty of Life Science Kumamoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologically confirmed diagnosis of NSCLC. 2) Non-small cell lung cancer with stage IB 3) Completely resected 4) more than lobectomy + ND2a 5) Neither previous chemotherapy nor radiotherapy before operation 6) Performance Status (ECOG) 0-2 7) Aged 20-75 years old 8)Have adequate organ function within 14 days before study entry a.Granulocyte count 1,500/mm3 or over b.Platelet count 100,000/mm3 or over c.Hb 9.0 g/dl or over d.AST(GOT) 2.5 x the Upper Limits of Normal (ULN) or under e.ALT(GPT) 2.5 x the Upper Limits of Normal (ULN) or under f.Total bilirubin 1.5 mg/dL or under g.Serum creatinine 1.5 mg/dl or under h.PaO2 60torr or over or SpO2 90% or over 9) Written informed consent to participate. 10) Possible to receive chemotherapy within 8 months after surgery
Exclusion criteria
Exclusion criteria: 1)Anamnesis of hypersensitivity to drugs 2)Massive pleural or pericardial effusion 3)With active double cancer 4)Severe complication (ileus , interstitial pneumonia , interstitial pneumonia , pulmonary fibrosis, uncontrolled diabetes , heart failure , renal failure, hepatic failure, and so on) 5) With active infections 6) With a difficult bowel movement 7) Pleural effusion, cardiac effusion, or cardiac effusion necessitating treatment. 8) Pregnancy or lactating patients 9) Uncontrolled psychiatric disease 10)With poor-controlled diabetes mellitus 11) Concurrent steroid therapy 12) With HBs or HCV 13) With HIV 14) Physician judged improper to entry this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The completion rate of four cycles | — |
Countries
Japan
Contacts
Public ContactKentaro Yoshimoto
Minami Kyushu National Hospital Department of Thoracic Surgery
Outcome results
None listed